Celebrating 20 Years of Scientific Progress in Treating EGFR+

It was 20 years ago this June that the first lung cancer gene mutation, EGFR positive, was discovered. Since then, we have seen a worldwide effort in research and development in the understanding and treatment of this disease. We are truly experiencing an exciting time with increasing targeted treatment options and precision medicines being developed and rolled out. There has been a seismic shift worldwide in the way we manage and live with EGFR+ lung cancer.

Clockwise from left: Cornwall, Surrey, Yorkshire, and Nottingham celebratory events.

The EGFR+ UK community came together on June 12th to celebrate the science that has revolutionised the treatment of EGFR+ lung cancer, giving us improved outcomes and hope. It was also a day for us to remember those we have lost to this disease.  Members marked the day in different ways: some raised a glass, some lit a candle, some went on a walk, some cuddled their new grandchild. What we shared was a moment to reflect and honour those who have come before and paved the way ahead for us all. 

Our social media channels have been awash with posts marking the anniversary: we drill down into the journey and advancements made in the understanding of EGFR+ over the past 20 years; we pay tribute to the worldwide collaborations and contributions made by pivotal leaders in the field who have shaped the landscape for patients; and we shared our hopes for the future. 

We would like to thank our Regional Ambassadors who have been busy organising anniversary picnics and lunches across the length and breadth of the UK.  It has been wonderful to see members join together and share in this celebration of science and hope.   

The past 20 years have revolutionised our understanding of lung cancer and its treatment.  I wonder what advancements we’ll see in the next few years? 

Natasha Loveridge, EGFR+ UK Marketing Trustee